BioStock: BioInvent anticipates strong influx of clinical data

BioInvent achieved solid progress throughout the third quarter, and CEO Martin Welschof anticipates a data-rich conclusion to 2024 that will further strengthen the company.
– Looking ahead to next year, we expect BioInvent’s strong momentum to persist, with seven essential data readouts across four drug candidates in clinical development.

Read the article at biostock.se:

https://www.biostock.se/en/2024/10/bioinvent-anticipates-strong-influx-of-clinical-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/